- Multicenter, multicohort, open-label, phase Ib trial evaluating the drug combination in patients with advanced solid tumors (including NSCLC, renal cell carcinoma, and melanoma)- ORR for the drug combination was higher for NSCLC (43%) than that in renal cell carcinoma (40%) and melanoma (10%)- However, patient subgroup analysis focusing on EGFR-mutant patients were not available from the study. This evidence concerns the gene EGFR and hereditary clear cell renal cell carcinoma.